MICHAEL S WEISS
CIK 1038977 · Executive Vice Chairman · last filed 2026-03-20
MICHAEL S WEISS is an Executive Vice Chairman who has filed 65 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for FBIOP, was dated Mar 20, 2026. Across all open-market trades the lifetime net is −$5.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.35B across reported positions. 22 SEC filings were submitted jointly with Fortress Biotech, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.35B
9
65
-$5.57M
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FBIOP | Executive Vice Chairman | 2,276,562 | $18.45 | $42.00M | $1.25M | 10 | 2026-03-20 |
| TGTX | CEO | 24,212,300 | $53.89 | $1.30B | -$3.35M | 23 | 2026-01-09 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | Director | 187,007 | $4.26 | $796.6K | $0 | 9 | 2025-05-30 |
| MBIO | Director | 1,060 | $0.51 | $538 | $0 | 5 | 2023-07-07 |
| AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Director | 22 | $0.35 | $8 | $0 | 1 | 2018-08-08 |
| FBIO | Exec. VC - Strategic Dev. | 533,411 | $2.52 | $1.34M | $0 | 2 | 2017-01-27 |
| Fortress Biotech, Inc. (CNDO) Delisted | Exec. VC - Strategic Dev. | 6,938,038 | — | — | $1.61M | 3 | 2014-11-10 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Executive Officer | 1,465,137 | — | — | -$5.08M | 6 | 2010-05-12 |
| XTLB | Director | — | $2.56 | — | $0 | 1 | 2008-11-04 |
Recent Filings
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-20 | FBIOP | Grant (A) | +475,424 | $0 | EDGAR |
| 2026-01-09 | TGTX | Grant (A) | +622,000 | $0 | EDGAR |
| 2025-11-07 | TGTX | Gift (G) | −4,668,843 | $0 | EDGAR |
| 2025-05-30 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Mixed | −124,812 | $64.5K | EDGAR |
| 2025-01-30 | TGTX | Grant (A) | +750,000 | $0 | EDGAR |
| 2025-01-03 | FBIOP | Grant (A) | +454,153 | $0 | EDGAR |
| 2024-12-17 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +12,638 | $0 | EDGAR |
| 2024-05-16 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +82,051 | $0 | EDGAR |
| 2024-01-08 | TGTX | Grant (A) | +1,001,908 | $0 | EDGAR |
| 2024-01-03 | FBIOP | Grant (A) | +216,465 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.